{"name":"Hansoh BioMedical R&D Company","slug":"hansoh-biomedical-rd-company","ticker":"","exchange":"","domain":"hansohbiomedicalrdcompany.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"immunology","drugs":[{"name":"HS-10374-matched placebo tablets","genericName":"HS-10374-matched placebo tablets","slug":"hs-10374-matched-placebo-tablets","indication":"Other","status":"phase_3"},{"name":"HS-10384 tablet Dose 1","genericName":"HS-10384 tablet Dose 1","slug":"hs-10384-tablet-dose-1","indication":"Other","status":"phase_2"},{"name":"HS-20117 combined HS-20093","genericName":"HS-20117 combined HS-20093","slug":"hs-20117-combined-hs-20093","indication":"Other","status":"phase_1"},{"name":"HS-20117 combined HS-20093 and 5-FU","genericName":"HS-20117 combined HS-20093 and 5-FU","slug":"hs-20117-combined-hs-20093-and-5-fu","indication":"Other","status":"phase_1"},{"name":"HS-10374","genericName":"HS-10374","slug":"hs-10374","indication":"Other","status":"phase_2"},{"name":"HS-10384 tablets","genericName":"HS-10384 tablets","slug":"hs-10384-tablets","indication":"Other","status":"phase_1"},{"name":"HS-10390","genericName":"HS-10390","slug":"hs-10390","indication":"Other","status":"phase_2"},{"name":"HS-20105","genericName":"HS-20105","slug":"hs-20105","indication":"Other","status":"phase_1"},{"name":"Placebo&HS-20137","genericName":"Placebo&HS-20137","slug":"placebo-hs-20137","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"HS-20093","genericName":"HS-20093","slug":"hs-20093","indication":"FGFR-altered solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Gemcitabine combined with docetaxel","genericName":"Gemcitabine combined with docetaxel","slug":"gemcitabine-combined-with-docetaxel","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HS-20089","genericName":"HS-20089","slug":"hs-20089","indication":"FGFR-altered solid tumors (Phase 3 development)","status":"phase_3"},{"name":"HS-20137","genericName":"HS-20137","slug":"hs-20137","indication":"FGFR-altered solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Drospirenone and Ethinyl Estradiol tablets","genericName":"Drospirenone and Ethinyl Estradiol tablets","slug":"drospirenone-and-ethinyl-estradiol-tablets","indication":"Oral contraception for prevention of pregnancy","status":"marketed"}]}],"pipeline":[{"name":"HS-20093","genericName":"HS-20093","slug":"hs-20093","phase":"phase_3","mechanism":"HS-20093 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors (Phase 3 development)"],"catalyst":""},{"name":"HS-10374-matched placebo tablets","genericName":"HS-10374-matched placebo tablets","slug":"hs-10374-matched-placebo-tablets","phase":"phase_3","mechanism":"This is a placebo tablet formulation used as a control comparator in clinical trials of HS-10374.","indications":[],"catalyst":""},{"name":"HS-10384 tablet Dose 1","genericName":"HS-10384 tablet Dose 1","slug":"hs-10384-tablet-dose-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-20117 combined HS-20093","genericName":"HS-20117 combined HS-20093","slug":"hs-20117-combined-hs-20093","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-20117 combined HS-20093 and 5-FU","genericName":"HS-20117 combined HS-20093 and 5-FU","slug":"hs-20117-combined-hs-20093-and-5-fu","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Drospirenone and Ethinyl Estradiol tablets","genericName":"Drospirenone and Ethinyl Estradiol tablets","slug":"drospirenone-and-ethinyl-estradiol-tablets","phase":"marketed","mechanism":"Drospirenone and ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity.","indications":["Oral contraception for prevention of pregnancy","Treatment of acne vulgaris (in some formulations)","Treatment of premenstrual dysphoric disorder (PMDD)"],"catalyst":""},{"name":"Gemcitabine combined with docetaxel","genericName":"Gemcitabine combined with docetaxel","slug":"gemcitabine-combined-with-docetaxel","phase":"phase_3","mechanism":"Gemcitabine and docetaxel work synergistically as chemotherapy agents—gemcitabine inhibits ribonucleotide reductase to disrupt DNA synthesis, while docetaxel stabilizes microtubules to prevent cell division—together targeting rapidly dividing cancer cells.","indications":["Non-small cell lung cancer","Breast cancer","Ovarian cancer","Pancreatic cancer"],"catalyst":""},{"name":"HS-10374","genericName":"HS-10374","slug":"hs-10374","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-10384 tablets","genericName":"HS-10384 tablets","slug":"hs-10384-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-10390","genericName":"HS-10390","slug":"hs-10390","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-20089","genericName":"HS-20089","slug":"hs-20089","phase":"phase_3","mechanism":"HS-20089 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors (Phase 3 development)"],"catalyst":""},{"name":"HS-20105","genericName":"HS-20105","slug":"hs-20105","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-20137","genericName":"HS-20137","slug":"hs-20137","phase":"phase_3","mechanism":"HS-20137 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Placebo&HS-20137","genericName":"Placebo&HS-20137","slug":"placebo-hs-20137","phase":"phase_3","mechanism":"HS-20137 is a small molecule with an unknown mechanism of action.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":14,"phaseCounts":{"phase_3":6,"phase_2":3,"phase_1":4,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}